Clinical Trials Logo

Mantle Cell Lymphoma Refractory clinical trials

View clinical trials related to Mantle Cell Lymphoma Refractory.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01389427 Completed - Clinical trials for Mantle Cell Lymphoma Refractory

Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Start date: November 2011
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open label, three arms, Phase IB study. A dose escalation phase of Temsirolimus (Toriselâ„¢) administered in intravenous (IV) at day 2, day 8 and day 15 in combination with three chemotherapies regimens for patients in relapsed/refractory Mantle Cell Lymphoma (MCL): - Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks for 6 cycles, - Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks for 6 cycles, - Rituximab-Aracytine high dose-Dexamethasone (R-DHA) administered every 4 weeks for 6 cycles.